Key Points
- Insider selling: Myomo insider Harry Kovelman sold 20,464 shares on May 27 at an average price of $1.00, totaling $20,464. He also sold another 11,536 shares on May 28 at $1.02.
- Stock and valuation snapshot: Myomo shares opened at $1.09, with a market cap of $42.12 million. The stock has traded between $0.61 and $3.14 over the past 52 weeks.
- Analyst and institutional activity: Craig Hallum reiterated a buy rating, and MarketBeat shows an average target price of $7.67. Institutional ownership remains significant, with several firms increasing stakes and holdings now at 44.99% of shares.
Myomo, Inc. (NYSEAMERICAN:MYO - Get Free Report) insider Harry Kovelman sold 20,464 shares of Myomo stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $1.00, for a total transaction of $20,464.00. Following the completion of the sale, the insider owned 120,154 shares in the company, valued at $120,154. The trade was a 14.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Harry Kovelman also recently made the following trade(s):
- On Thursday, May 28th, Harry Kovelman sold 11,536 shares of Myomo stock. The stock was sold at an average price of $1.02, for a total transaction of $11,766.72.
Myomo Price Performance
Myomo stock opened at $1.09 on Friday. The firm has a market capitalization of $42.12 million, a PE ratio of -3.03 and a beta of 1.39. The company's 50-day moving average is $0.81 and its 200-day moving average is $0.85. Myomo, Inc. has a fifty-two week low of $0.61 and a fifty-two week high of $3.14. The company has a debt-to-equity ratio of 1.21, a current ratio of 2.73 and a quick ratio of 2.36.
Analyst Ratings Changes
Separately, Craig Hallum restated a "buy" rating on shares of Myomo in a research note on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, Myomo currently has an average rating of "Buy" and an average target price of $7.67.
Get Our Latest Stock Report on MYO
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of MYO. Cubist Systematic Strategies LLC increased its stake in shares of Myomo by 157.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 49,101 shares of the company's stock worth $236,000 after purchasing an additional 30,028 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Myomo during the 1st quarter worth about $75,000. Jane Street Group LLC boosted its holdings in shares of Myomo by 84.2% during the 1st quarter. Jane Street Group LLC now owns 162,658 shares of the company's stock worth $782,000 after buying an additional 74,338 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Myomo during the 1st quarter worth about $114,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Myomo by 160.8% during the 2nd quarter. Geode Capital Management LLC now owns 669,281 shares of the company's stock worth $1,446,000 after buying an additional 412,631 shares during the period. 44.99% of the stock is currently owned by institutional investors and hedge funds.
Myomo Company Profile
(
Get Free Report)
Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company's flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users' own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.
Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
